Statement release from Soren Weis Dahl CEO, #Prophylix AS regarding the current status of the manufacture and development of ~#NAITgam.
22 August 2019
Prophylix AS has entered into a definitive agreement with Rallybio, a
U.S.-based drug development company, under which Rallybio acquires
Prophylix’s orphan drug programs, NAITgam and a follow-on therapy.
NAITgam is a plasma-derived HPA-1a antibody in early clinical development
for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT),
a devastating, life-threatening disorder in fetuses and newborns.